707 related articles for article (PubMed ID: 27771182)
1. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
2. A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses.
Cai Y; Ku Z; Liu Q; Leng Q; Huang Z
Vaccine; 2014 May; 32(21):2406-12. PubMed ID: 24657161
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
5. Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71.
Zhang C; Yang Y; Chi Y; Yin J; Yan L; Ku Z; Liu Q; Huang Z; Zhou D
Vaccine; 2015 Sep; 33(39):5087-94. PubMed ID: 26296491
[TBL] [Abstract][Full Text] [Related]
6. A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice.
Ku Z; Liu Q; Ye X; Cai Y; Wang X; Shi J; Li D; Jin X; An W; Huang Z
Vaccine; 2014 Jul; 32(34):4296-303. PubMed ID: 24950363
[TBL] [Abstract][Full Text] [Related]
7. The compatibility of inactivated-Enterovirus 71 vaccination with Coxsackievirus A16 and Poliovirus immunizations in humans and animals.
Mao Q; Wang Y; Shao J; Ying Z; Gao F; Yao X; Li C; Ye Q; Xu M; Li R; Zhu F; Liang Z
Hum Vaccin Immunother; 2015; 11(11):2723-33. PubMed ID: 25715318
[TBL] [Abstract][Full Text] [Related]
8. Optimization and Characterization of Candidate Strain for Coxsackievirus A16 Inactivated Vaccine.
Li J; Liu G; Liu X; Yang J; Chang J; Zhang W; Yu XF
Viruses; 2015 Jul; 7(7):3891-909. PubMed ID: 26193302
[TBL] [Abstract][Full Text] [Related]
9. Chimeric enterovirus 71 virus-like particle displaying conserved coxsackievirus A16 epitopes elicits potent immune responses and protects mice against lethal EV71 and CA16 infection.
Luo J; Huo C; Qin H; Hu J; Lei L; Pan Z
Vaccine; 2021 Jul; 39(30):4135-4143. PubMed ID: 34116877
[TBL] [Abstract][Full Text] [Related]
10. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
11. A Broadly Cross-protective Vaccine Presenting the Neighboring Epitopes within the VP1 GH Loop and VP2 EF Loop of Enterovirus 71.
Xu L; He D; Yang L; Li Z; Ye X; Yu H; Zhao H; Li S; Yuan L; Qian H; Que Y; Kuo Shih JW; Zhu H; Li Y; Cheng T; Xia N
Sci Rep; 2015 Aug; 5():12973. PubMed ID: 26243660
[TBL] [Abstract][Full Text] [Related]
12. Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine.
Fan S; Liao Y; Jiang G; Jiang L; Wang L; Xu X; Feng M; Yang E; Zhang Y; Cui W; Li Q
Vaccine; 2020 Feb; 38(8):2034-2044. PubMed ID: 31982260
[TBL] [Abstract][Full Text] [Related]
13. VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.
Chen FH; Liu X; Fang HL; Nan N; Li Z; Ning NZ; Luo DY; Li T; Wang H
Front Immunol; 2019; 10():2564. PubMed ID: 31787970
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of bivalent versus monovalent vaccines against hand, foot and mouth disease.
Liu D; Leung K; Jit M; Yu H; Yang J; Liao Q; Liu F; Zheng Y; Wu JT
Clin Microbiol Infect; 2020 Mar; 26(3):373-380. PubMed ID: 31279839
[TBL] [Abstract][Full Text] [Related]
15. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
16. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
17. The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease.
Lim H; In HJ; Lee JA; Sik Yoo J; Lee SW; Chung GT; Choi YK; Chung JK; Cho SJ; Lee JW
Vaccine; 2018 Jun; 36(24):3445-3452. PubMed ID: 29739716
[TBL] [Abstract][Full Text] [Related]
18. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a Trivalent Hand, Foot, and Mouth Disease Vaccine against Enterovirus 71 and Coxsackieviruses A16 and A6 in Mice.
Caine EA; Fuchs J; Das SC; Partidos CD; Osorio JE
Viruses; 2015 Nov; 7(11):5919-32. PubMed ID: 26593938
[TBL] [Abstract][Full Text] [Related]
20. Active immunization with a Coxsackievirus A16 experimental inactivated vaccine induces neutralizing antibodies and protects mice against lethal infection.
Cai Y; Liu Q; Huang X; Li D; Ku Z; Zhang Y; Huang Z
Vaccine; 2013 Apr; 31(18):2215-21. PubMed ID: 23499596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]